<DOC>
	<DOCNO>NCT00004003</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat adult patient stage III stage IV pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage III Stage IV Pancreatic Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall survival patient unresectable stage III IV pancreatic adenocarcinoma treat gemcitabine , cisplatin , fluorouracil . II . Determine resectability rate curative intent patient unresectable stage III pancreatic adenocarcinoma treat regimen . III . Assess tolerability toxicity treatment regimen patient population . IV . Evaluate regimen term response rate , response duration , overall time disease progression patient . V. Evaluate quality life patient . OUTLINE : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 , follow cisplatin IV 30 minute day 1 15 . Patients receive fluorouracil continuous infusion day 1-15 . Courses repeat every 28 day . Quality life assess every 28 day . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm pancreatic adenocarcinoma Unresectable locally advance ( stage III ) OR Metastatic ( stage IV ) Gallbladder biliary tract cancer allow No endocrine tumor lymphoma pancreas No CNS metastases PATIENT CHARACTERISTICS : Age : Adult Performance status : SWOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL AST great 3.0 time upper limit normal Renal : Creatinine great 1.5 mg/dL Other : No active infection No serious systemic disorder No active malignancy within past year except curatively treat basal cell skin cancer carcinoma situ cervix Must central venous access device ( i.e. , Infusaport PASPORT ) Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy locally advance metastatic disease At least 6 month since prior adjuvant chemotherapy No prior gemcitabine Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>